Histone Deacetylase Inhibitor Discovery Services

Histone deacetylases (HDACs) are enzymes that remove acetyl groups from histones, leading to chromatin condensation and transcriptional repression. This mechanism plays a pivotal role in cellular aging and senescence. Research has shown that altering HDAC activity can reverse age-related changes in gene expression. HDAC inhibitors have been identified as promising candidates for rejuvenating cellular function, promoting longevity, and mitigating age-associated decline.

Fig. 1 Influence of HDAC inhibition on the hallmarks of aging. (McIntyre RL, et al., 2019)

With decades of experience, CD BioSciences is dedicated to helping clients develop innovative HDAC inhibitors to alleviate the effects of aging and aging-related diseases. We aim to provide reliable solutions for pharmaceutical companies pursuing novel anti-aging therapeutics.

Overview of Our Histone Deacetylase Inhibitor Discovery Services for Promoting Healthy Aging

Chemical synthesis of histone deacetylase inhibitors

CD BioSciences utilizes advanced synthetic methodologies to develop novel HDAC inhibitors with anti-aging effects. Our experienced chemists use structure-based drug design and high-throughput screening tailored to specific HDAC targets linked to aging and aging-related diseases.

Our company employs advanced technology for multistep synthesis, allowing for the production of compounds with high purity and efficacy. We integrate nuclear magnetic resonance (NMR) and mass spectrometry (MS) techniques for detailed structural elucidation of synthesized HDAC inhibitors.

In vitro and in vivo histone deacetylase activity assays

To validate the efficacy of synthesized HDAC inhibitors, we assist clients in conducting comprehensive in vitro and in vivo assays. Our in vitro assays include biochemical evaluations using purified HDAC enzymes and cellular models to measure the impact of HDAC inhibitors on HDAC activity and downstream effects on gene expression. Additionally, we help clients determine the IC₅₀ values (inhibitory concentrations) and uncover the potential off-target effects of HDAC inhibitors.

Our in vivo studies involve administering HDAC inhibitors in aging animal models, allowing us to help clients assess pharmacodynamics, potential therapeutic effects, and safety profiles. We help our clients assess the impact of HDAC on lifespan and the hallmarks of aging. Our thorough assessments allow for the selection of promising inhibitors for further development.

Epigenomic profiling

We offer epigenomic profiling services that elucidate changes in histone modifications and gene expression patterns resulting from HDAC inhibition. We assist our clients in evaluating whether age-related chromatin deacetylation can be reversed, as well as acetylation of histones near pro-longevity genes. Through techniques such as ChIP sequencing and RNA sequencing, we enable clients to dissect the complex interplay between epigenetic modifications and gene regulatory networks, providing invaluable data for their research and development efforts.

Analysis of the Role of Histone Deacetylase Inhibitors in Aging

• Inflammaging. Inflammaging, the chronic, low-grade inflammation associated with aging, contributes to various age-related diseases. We help clients analyze how HDAC inhibitors exert anti-inflammatory effects by altering the expression of cytokines and other inflammatory markers.
• Premature aging. We help clients analyze the role of HDAC inhibitors in the molecular mechanisms underlying premature aging, often exacerbated by stress, environmental factors, and genetic predispositions. Our experts also investigate whether HDAC inhibitors reverse some of the cellular hallmarks of aging, such as telomere shortening and mitochondrial dysfunction.

CD BioSciences is devoted to HDAC inhibitor discovery, offering comprehensive services including chemical synthesis, activity assays, and epigenomic profiling. If you are interested in our services, please feel free to contact us or make an online inquiry.

Reference

1. McIntyre RL, et al. From molecular promise to preclinical results: HDAC inhibitors in the race for healthy aging drugs. EMBO Mol Med, 2019, 11 (9): e9854.